NYSE · SYK
Healthcare · Medical - Devices
$277.33
Up+$0.36 (+0.13%)
Updated Oct 10, 2026, 7:43 PM
SID Score
5.2/10
Composite research score
Smart Money
47/100
Neutral
Price performance · SYK
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
SYK closed at $277.33 after 21 trading sessions, up 0.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $277.01 | $281.58 | $276.53 | $277.33 | 1.48M |
| Oct 8, 2026 | $275.72 | $277.97 | $271.67 | $276.97 | 2.98M |
| Oct 7, 2026 | $280.16 | $281.96 | $274.45 | $275.40 | 1.92M |
| Oct 6, 2026 | $279.37 | $284.53 | $277.10 | $278.20 | 2.86M |
| Oct 5, 2026 | $275.50 | $286.09 | $275.00 | $285.22 | 3.33M |
| Oct 2, 2026 | $273.185 | $276.97 | $271.213 | $275.43 | 2M |
| Oct 1, 2026 | $275.60 | $278.51 | $271.341 | $272.96 | 2.46M |
| Sep 30, 2026 | $276.26 | $279.372 | $273.05 | $275.39 | 2.93M |
| Sep 29, 2026 | $277.00 | $280.165 | $274.305 | $278.77 | 2.79M |
| Sep 28, 2026 | $273.50 | $276.94 | $271.10 | $275.31 | 2.49M |
| Sep 25, 2026 | $269.93 | $275.84 | $268.69 | $272.36 | 2.34M |
| Sep 24, 2026 | $273.22 | $275.7142 | $269.725 | $269.75 | 2.29M |
| Sep 23, 2026 | $274.46 | $277.1035 | $271.445 | $273.40 | 2.72M |
| Sep 22, 2026 | $277.00 | $278.99 | $274.99 | $275.09 | 2.36M |
| Sep 21, 2026 | $274.58 | $276.868 | $272.00 | $274.19 | 2.76M |
| Sep 18, 2026 | $278.02 | $279.26 | $274.37 | $275.12 | 4.81M |
| Sep 17, 2026 | $286.10 | $286.125 | $279.09 | $280.13 | 2.37M |
| Sep 16, 2026 | $280.34 | $290.51 | $279.875 | $284.76 | 3.4M |
| Sep 15, 2026 | $281.00 | $282.69 | $277.62 | $281.50 | 3.46M |
| Sep 14, 2026 | $282.31 | $287.165 | $280.67 | $281.87 | 2.94M |
| Sep 11, 2026 | $270.72 | $277.00 | $267.00 | $275.56 | 3.72M |
The latest Smart Investors Daily articles mentioning SYK.
Company
Market Activity
Research & News
SYK research
Company profile and research snapshot.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Truist Securities | Hold | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 30, 2026 | Stifel | Buy | — |
| Sep 22, 2026 | TD Cowen | Hold | — |
| Sep 18, 2026 | Canaccord Genuity | Buy | — |
Generated Oct 10, 2026, 5:20 PM
Stryker shares are essentially flat despite significant corporate turmoil, as the medical device giant announced a CEO transition following a 25-26% stock decline over the past year. The muted price action suggests investors are digesting both the management shake-up and emerging consensus that the stock may now offer attractive valuation opportunities after its sharp pullback.
Bottom line: Stryker finds itself at an inflection point: the CEO change signals board accountability while the 25%+ stock decline has created potential valuation opportunities, yet near-term growth concerns and execution risks remain. Investors should monitor the new CEO's strategic announcements and upcoming earnings for evidence of turnaround momentum before increasing exposure.
Yahoo · Oct 9, 2026
Stryker Corporation (NYSE:SYK) traded at around $275 on October 7, down 1.01% on the day and 24.85% lower over twelve months. The company said on October 6 that Kevin Lobo will become executive chairman and Spencer Stiles will become chief executive, both effective January 1. The succession arrives with the shares 30% below their 52-week […]
Yahoo · Oct 9, 2026
Mar Vista Investment Partners, LLC, an investment management company, released its third-quarter 2026 investor letter for “Mar Vista U.S. Quality Strategy”. The letter can be downloaded here. During the third quarter of 2026, financial markets faced significant macroeconomic pressures, such as rising interest rates and inflation, which typically impact equity valuations. However, the S&P 500® Index […]
Yahoo · Oct 9, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Yahoo · Oct 8, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SYK.
